Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Go back to Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
(NASDAQ: SKYE) Delayed: 1.45 -0.12 (7.64%)
Previous Close $1.57    52 Week High $ 
Open $1.58    52 Week Low $ 
Day High $1.58    P/E N/A 
Day Low $1.45    EPS $ 
Volume 16,759